However, more recently, a new class of drugs has been specifically developed for migraine prevention: calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) targeting the CGRP or its receptor, as well as oral CGRP receptor antagonists [128]. The gene discussed is CALCA; the disease is migraine disorder.